Founded in 2020 and based in Glasgow, NeuroVLC was formed by combining the world-class research of the free-space optical communication and neurophotonics groups, based in the University of Strathclyde’s Institute of Photonics.

Our primary mission is to advance the understanding of the intricate workings of the brain.

With our proprietary low-power, low-weight wireless neural recording system, our technology holds the potential to capture and transmit data at much larger scales. This capability positions NeuroVLC to make substantial contributions to the development of tools for neuroscience research, novel treatments, and targeted therapies for various brain-related health conditions and diseases.


Start Date









The Journey

Since our formation in 2020, NeuroVLC has aimed to support neuroscience, building upon the research in free-space optical communication and neurophotonics at the University of Strathclyde’s Institute of Photonics. Our wireless neural recording system, optimized for low power and weight, and has to potential to capture and transmit brain data on an unprecedented scale.

Following our formal incorporation in 2020, the Scottish Enterprise SMART award and Alpha Omega investments in 2021 further validated our vision and mission.

More recently this was additionally supported with a £500,000 Innovate UK grant and investments from Apollo Informal Investment, Gabriel Investment Syndicate, and the University of Strathclyde, further cementing our position as an emerging contributor in neurotechnology.

Developing something novel is already exhilarating, but by taking it to the market you can potentially make a much more significant impact. The field of neuroscience is exceptionally intriguing and dynamic. It’s an incredibly exciting time to be part of this growing field, as new technologies and research methodologies continually emerge, offering unprecedented insights into the brain’s complexities. The prospects for transformative impact is immense, and NeuroVLC is very excited to be part of this journey.

Dr. Gábor Várkonyi

Contact Form


    £31,786.28 ICURe fund - Cohort 25


    Company Incorporation


    £85,000 Scottish Enterprise SMART award


    £43,000 investment Alpha Omega


    Spin-out from University of Strathclyde


    £500,000 Innovate UK grant


    Patent GBGB1715910.4A granted


    £170,000 investment – Apollo Informal Investment, Gabriel Investment Syndicate, University of Strathclyde

    What companies had to say about the Innovate UK ICURe programme?

    Future Goals

    Looking ahead, our primary goal is to continue serving the neuroscience community by pushing the boundaries of what’s possible, offering cutting-edge solutions that enable researchers and end-users to gain unparalleled insights into the brain.

    As we grow and evolve, our focus remains on optimizing workflows for pharmaceutical companies, streamlining the research and development process to accelerate the discovery and delivery of new treatments. We understand the urgent need to bridge the gap between scientific research and clinical application, and we are committed to providing the tools and technologies necessary to make this a reality.

    Our ultimate hope is to contribute to significant advancements in brain-related health conditions and diseases, ultimately improving patient outcomes and quality of life. We envision a future where our technologies play a vital role in shaping the understanding and treatment of neurological disorders, paving the way for more effective therapies and personalized interventions.